在接受酸抑制治疗的患者中感染:一项大型队列研究与倾向性得分匹配
Ilsoo Kim1, Joon Sung Kim2, Jae Myung Park3
1Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, ilsookim86@gmail.com.
Digestive diseases (Basel, Switzerland)
|July 27, 2025
概括
质子抑制剂 (PPI) 与基因组二受体对抗剂 (H2RAs) 相比,增加了 Clostridioides difficile感染 (CDI) 的风险. 泰戈普拉赞没有显著增加CDI风险,这表明仔细选择抑制酸的药物至关重要.
科学领域:
- 胃肠病学 胃肠病学
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 困难菌感染 (CDI) 对接受酸抑制治疗的患者来说是一个严重的风险.
- 评估CDI与不同抑制酸的药物之间的比较风险至关重要.
研究的目的:
- 为了比较使用质子抑制剂 (PPI),组胺二受体对抗剂 (H2RAs) 和泰戈普拉赞的患者中CDI的风险.
- 评估抑制酸性治疗对CDI发病率的影响.
主要方法:
- 追溯观察队列研究606460个人,与22431匹配的参与者.
- 倾向性得分匹配用于比较PPI,H2RA和tegoprazan用户之间的结果.
- 主要结局是药物开始后12周内CDI发生率.
主要成果:
- 与H2RA相比,质子抑制剂 (PPI) 与CDI的相对风险 (RR: 1.86) 相对较高.
- 泰戈普拉赞与H2RA相比,CDI风险没有显著增加 (RR:1.07).
- 随着酸抑制剂使用时间的延长,CDI风险增加;没有发现剂量依赖或严重的CDI差异.
结论:
- 质子抑制剂 (PPI) 与Clostridioides difficile感染 (CDI) 的风险比H2RAs更大.
- 泰戈普拉桑似乎在CDI风险方面具有与H2RAs相似的安全概况.
- 谨慎选择抑制酸性的药物是必不可少的,特别是对于高风险患者群体.
更多相关视频
相关概念视频
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
525
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
525
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
446
In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
However, this neutralization reaction between...
446
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
203
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
203
Drugs for Treatment of Ulcerative Colitis in IBD
239
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
239
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
570
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
570


